These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33565048)

  • 1. EQ-5D-Y Value Set for Slovenia.
    Prevolnik Rupel V; Ogorevc M;
    Pharmacoeconomics; 2021 Apr; 39(4):463-471. PubMed ID: 33565048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value Set for the EQ-5D-Y-3L in Hungary.
    Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.
    Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W
    Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EQ-5D-Y Value Set for Germany.
    Kreimeier S; Mott D; Ludwig K; Greiner W;
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EQ-5D-5L Value Set for Slovenia.
    Prevolnik Rupel V; Ogorevc M
    Pharmacoeconomics; 2023 Nov; 41(11):1515-1524. PubMed ID: 37341959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating an EQ-5D-Y-3L Value Set for Brazil.
    Espirito Santo CM; Miyamoto GC; Santos VS; Ben ÂJ; Finch AP; Roudijk B; de Jesus-Moraleida FR; Stein AT; Santos M; Yamato TP
    Pharmacoeconomics; 2024 Sep; 42(9):1047-1063. PubMed ID: 38954389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An EQ-5D-Y-3L Value Set for Belgium.
    Dewilde S; Roudijk B; Tollenaar NH; Ramos-Goñi JM
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):169-180. PubMed ID: 36316544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
    Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
    Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating an EQ-5D-Y-3L Value Set for China.
    Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Value Set for the EQ-5D-Y-3L in the Netherlands.
    Roudijk B; Sajjad A; Essers B; Lipman S; Stalmeier P; Finch AP
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):193-203. PubMed ID: 36216977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
    Mott DJ; Shah KK; Ramos-Goñi JM; Devlin NJ; Rivero-Arias O
    Med Decis Making; 2021 Jul; 41(5):584-596. PubMed ID: 33733920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Valuation Protocol for the EQ-5D-Y-3L.
    Ramos-Goñi JM; Oppe M; Stolk E; Shah K; Kreimeier S; Rivero-Arias O; Devlin N
    Pharmacoeconomics; 2020 Jul; 38(7):653-663. PubMed ID: 32297224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
    Yang Z; Jiang J; Wang P; Wu J; Fang Y; Feng D; Xi X; Luo N
    Value Health; 2023 Jul; 26(7):968-973. PubMed ID: 36921897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Graczyk K; Niewada M
    Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EQ-5D-5L valuation study for Trinidad and Tobago.
    Bailey H; Jonker MF; Pullenayegum E; Rencz F; Roudijk B
    Health Qual Life Outcomes; 2024 Jul; 22(1):51. PubMed ID: 38956543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.